Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151 Meeting Abstract
| Authors: | Suarez, C.; Choueiri, T. K.; McDermott, D. F.; Escudier, B.; Atkins, M. B.; Powles, T. B.; Rini, B. I.; Motzer, R. J.; Pal, S. K.; Fong, L.; De Giorgi, U.; Wang, Y.; Khaznadar, T.; Di Nucci, F.; Kaiser, C.; Tayama, D.; Donskov, F. |
| Abstract Title: | Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151 |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy283.082 |
| Language: | English |
| ACCESSION: | WOS:000459277302056 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy283.082 |
| Notes: | Meeting Abstract: 873P -- Appears on page viii308 of the abstract book -- Source: Wos |
